Why the study?
Do glucagon-like peptide-1 receptor agonists and dual GIP/GLP-1 receptor agonists improve heart failure symptoms and reduce heart failure events in patients with heart failure (specifically HFpEF and HFrEF)?
Do glucagon-like peptide-1 receptor agonists and dual GIP/GLP-1 receptor agonists improve heart failure symptoms and reduce heart failure events in patients with heart failure (specifically HFpEF and HFrEF)?
Answers are grounded in this paper and cite their sources.
Current clinical trial evidence strongly supports the use of GLP-1RAs (specifically semaglutide) and dual GIP/GLP-1RAs (tirzepatide) to improve symptoms, physical function, and clinical outcomes in patients with obesity-related HFpEF (with or without T2D), while discouraging their primary use in HFrEF.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), established treatments for type 2 diabetes and obesity, exhibit cardiovascular benefits extending to heart failure (HF) with preserved ejection fraction (HFpEF). Mechanisms contributing to HF improvement include significant weight loss, blood pressure reduction, enhanced glycaemic control, anti-inflammatory effects and potential direct cardioprotective and vascular actions. Although cardiovascular outcome trials provided initial positive signals, dedicated HFpEF trials confirmed the efficacy of GLP-1RAs in HFpEF patients with obesity and/or diabetes. In some trials, GLP-1RAs significantly improved weight, symptoms of HF and HF events. Current evidence strongly supports GLP-1RAs in patients with HFpEF and obesity, with or without type 2 diabetes. The data do not support their use solely for HF with reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Abdelhamid et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: